Research Use Only vs. Compounded vs. FDA-Approved: The Three Regulatory Lanes for Peptides in Your Practice

Every peptide that enters a practice arrives through one of three regulatory lanes. It is an FDA-approved drug, it is a compounded preparation from a 503A pharmacy or a 503B outsourcing facility, or it is a Research Use Only (RUO) product. The lane decides how the product is labeled, who can dispense it, what the patient signs, and what the practice is allowed to say about it. Practices get into trouble when they blur the lanes: describing an RUO product as an approved drug, or assuming a compounded peptide can be stocked and resold like a supplement. Here is what each lane means and how a compliant program keeps them separate.

This article is general information, not legal advice. Rules change and vary by state. Review your program with counsel who knows your state's medical board and pharmacy regulations.

What are the three regulatory lanes for peptides?

Lane 1: FDA-approved drugs. Semaglutide, tirzepatide, and liraglutide are peptides that went through full FDA review. They carry approved indications, prescribing information, and a pharmacy dispensing pathway. More than 100 peptide drugs hold FDA approval, and peptides account for roughly 10 percent of new drug approvals. In this lane the practice prescribes, a pharmacy dispenses, and the practice may market the drug for its approved use.

Lane 2: Compounded preparations. A compounding pharmacy prepares the product from bulk substances. Two types exist:

• 503A pharmacies compound patient-specific prescriptions. One prescription, one patient, and the product can ship to that patient's home. A 503A product cannot be bought in bulk and held as office stock.
• 503B outsourcing facilities operate under cGMP and may produce office stock for provider-administered use across multiple patients.

Either way, the pharmacy may only use substances the FDA allows for compounding: components of approved drugs, substances with a USP monograph, or substances on the FDA's 503A bulks list. Many popular research peptides fall outside all three, which is the subject of the next section.

Lane 3: Research Use Only. An RUO product has not been submitted to the FDA for review as a drug, is not labeled with therapeutic claims, and is not represented as a treatment for any disease. The manufacturer labels it accurately, and the responsibility shifts to the practice to describe it, document it, and dispense it accurately under physician oversight. RUO is a labeling category, not a loophole. What makes it defensible is that everything the practice says and signs matches the label.

Why does the FDA 503A bulks list matter to a practice?

Because it decides whether a compounding pharmacy can legally make a given peptide at all. The FDA sorts nominated bulk drug substances into three categories:

• Category 1: substances under evaluation that may be compounded in the meantime.
• Category 2: substances the FDA has flagged for a significant safety concern. Not eligible for compounding.
• Category 3: substances nominated without enough supporting information. Not eligible for compounding.

In 2023 the FDA placed a group of popular peptides, including BPC-157, in Category 2, citing concerns such as immunogenicity and impurity risk. The FDA has revised the list since, and a substance leaving Category 2 does not automatically land in Category 1, so "no longer flagged" and "eligible to compound" are different things. Check the current list on the FDA's bulk drug substances used in compounding page before relying on any pharmacy's word for it.

The practical rule for a practice: if a pharmacy offers to compound a peptide, ask which basis makes it eligible. If the answer is vague, the product may not be in the compounded lane at all, no matter what the invoice says.

What does Research Use Only labeling require from a practice?

Consistency. An RUO program is defensible when the label, the chart, the consent form, the staff script, and the website all describe the product the same way. Six practices hold that together:

1. 1The label matches reality. The product is labeled RUO by the manufacturer, and nothing the practice adds contradicts it.
2. 2No approval claims. Staff never describe an RUO product as FDA-approved, even when the active ingredient resembles an approved drug. "Is this FDA approved?" gets the accurate category answer for that product, every time.
3. 3No disease claims. The practice does not market an RUO product to diagnose, treat, cure, or prevent a disease. Patient conversations follow the same line.
4. 4Consent written for the category. A generic supplement waiver does not cover an RUO product. The consent form names the category, states that the product is not FDA-approved, and documents that the patient understood it. The onboarding steps in Starting Patients on Peptides: A Clinical Framework for the First 90 Days build the consent into the first visit.
5. 5Physician oversight. RUO does not mean unsupervised. A licensed provider evaluates the patient, decides on the protocol, and schedules the follow-up. Delegation follows your state's scope-of-practice rules.
6. 6Verification on file. Every AgeREcode vial carries a QR code for independent third-party verification through Chromate.org. Logging the lot and its verification result gives the chart a purity and potency record. The diligence questions in Peptide Sourcing 101: What cGMP, ISO-7, and Third-Party Verification Actually Mean cover what to ask a supplier before the first order.

How do the lanes differ in day-to-day operations?

What are the common mistakes that create risk?

• Borrowing an approved drug's status. A compounded or RUO peptide is not FDA-approved because a related product is. Semaglutide the approved drug and a compounded semaglutide preparation sit in different lanes.
• Treating 503A product as inventory. Patient-specific prescriptions cannot be bought in bulk, shelved, and resold. That is the line between 503A and 503B, and crossing it is a pharmacy-law problem, not a paperwork problem.
• One consent form for everything. A single waiver that covers supplements, compounded drugs, and RUO products covers none of them well. Each lane gets its own language.
• Marketing that outruns the label. A website that promises to treat a condition with an RUO product creates a disease claim the label does not support. The marketing copy should be as accurate as the consent form.
• Ignoring state rules. Medical boards, pharmacy boards, corporate practice of medicine rules, and delegation limits for nurse practitioners and med spa staff vary by state. Federal lane rules are the floor, not the ceiling.
• No lot records. If a patient asks what they took six months ago, the chart should answer with a lot number and a verification result.

How does AgeREcode support the compliance side?

By building the paperwork around the lane the products live in. AgeREcode provides customizable informed consent forms, patient handouts, treatment logs, and staff SOPs, all written around Research Use Only labeling, physician oversight, and accurate disclosure. The Clinical Operator's Manual covers protocols, contraindications, and patient education so the clinical story and the compliance story match. Every vial carries QR verification through Chromate.org, and the products are made in a cGMP-certified, ISO-7 cleanroom facility in Tampa, Florida.

A practice that runs the program this way has a straightforward answer to every question a patient, an auditor, or a board might ask: here is what the product is, here is what we told the patient, here is what they signed, and here is the verification. That is the whole point. The categories overview in GLP-1s Are Just the Beginning: The Peptide Categories Patients Are Asking About shows which products fit which patient need once the compliance foundation is in place.

Frequently Asked Questions